Vivus Inc. (VVUS) Pops on FDA comments

Shares of Vivus Inc. (VVUS) just spiked 12% to $11.25 HOD on heavy volume (over 7mln) with strength being attributed to newswire headlines that The Food and Drug Administration [FDA] doesn’t need to revisit Fen-Phen risks, the recalled Vivus and Arena Pharmaceuticals, Inc. (ARNA) diet treatment that caused heart valve damage.

“The FDA doesn’t need to revisit fen-phen’s risks because none of the new treatments contain the same ingredient mix”, Eric Colman, deputy director of the agency’s Division of Metabolism and Endocrinology Products, said today in a telephone interview with Bloomberg News.

Meet Jasper - The AI Writer

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.